Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.

By M. Boeckh, W. Leisenring, S. Riddell, R. Bowden, Meei-Li W Huang, D. Myerson, Terry L. Stevens-Ayers, M. Flowers, T. Cunningham, L. Corey. Blood, 2002

606 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients (2004, background): “This patient subset may therefore be unable to mount an appropriate immune response to control the emerging level of CMV replication after discontinuation of antiviral prophylaxis (28).”
Hematopoietic stem-cell transplantation. (2006, background): “After allogeneic HSCT, around 30% of patients will experience reactivation of latent CMV infection, which usually occurs within the late posttransplant period and is associated with a 46% mortality.(64) The immune response against CMV is predominantly mediated by the cellular immune system.”